Director Sells $5.9M in Protagonist Therapeutics Stock Following Option Exercise
PTGX has more than doubled off its 52-week low of $42.85.
Summary
Director Bryan Giraudo sold nearly $6 million worth of Protagonist Therapeutics common stock after exercising options, continuing a trend of insider sales following recent positive financial news.
Key Events · Ownership and Investor Activity · PTGX
-
Director Sells Shares
Director Bryan Giraudo sold 59,130 shares of common stock for a total of $5,918,880 through open market transactions on May 7-8, 2026.
-
Option Exercise Precedes Sale
The sale followed the exercise of 36,000 stock options for $238,560 on May 7, 2026, indicating a 'sell-to-cover' or 'exercise and sell' strategy.
-
Timing Near 52-Week Highs
These transactions occurred with the stock trading near its 52-week high, shortly after the company reported a profitable Q1 2026 and a significant milestone payment.
-
Part of Broader Insider Selling Trend
This sale contributes to a net insider distribution of over $13 million in the last 90 days, indicating a pattern of insider selling.
Analysis · PTGX · Life Sciences
This significant insider sale by a director, occurring shortly after the company reported a profitable Q1 and a major milestone payment, and with the stock trading near its 52-week high, suggests a lack of conviction despite recent positive developments. The sale contributes to a broader pattern of insider distribution observed over the last 90 days.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.5% of the 993 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.86%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTGX was trading at $103.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $42.85 to $107.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.